Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study
Φόρτωση...
Ημερομηνία
Συγγραφείς
Naka, K. K.
Pappas, K.
Papathanassiou, K.
Papamichael, N. D.
Kazakos, N.
Kanioglou, C.
Makriyiannis, D.
Katsouras, C. S.
Liveris, K.
Tsatsoulis, A.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Cardiovasc Diabetol
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
BACKGROUND: Thiazolidinediones, used for the treatment of patients with type 2 diabetes mellitus (DM2), are associated with an increased incidence of heart failure. We sought to investigate the effects of pioglitazone on novel echocardiographic indices of left ventricular (LV) diastolic function in DM2 patients with LV diastolic dysfunction (LVDD). METHODS: Eighty-eight asymptomatic DM2 patients on metformin and/or sulfonylureas, aged 64.5 +/- 7.7 years, without known cardiovascular disease, with normal LV systolic function and evidence of LVDD were randomly assigned to pioglitazone 30 mg/day (n = 42) or an increase in dose of other oral agents (n = 39) for 6 months. All patients underwent transthoracic conventional and Tissue Doppler Imaging echocardiography at baseline and follow-up. The primary end-point was change in early diastolic velocity of the mitral annulus (E'). RESULTS: Improvement of glycaemic control was similar in the 2 groups. A significant difference (p < 0.05) between the 2 groups was found in the treatment-induced changes in fasting insulin, the insulin resistance index HOMA, HDL cholesterol, triglycerides, diastolic blood pressure (all in favor of pioglitazone) and in body weight (increase with pioglitazone). No significant changes were observed in any echocardiographic parameter in either group and did not differ between groups (p = NS for all). E' increased non-significantly and to a similar extent in both groups (p = NS). CONCLUSIONS: In asymptomatic DM2 patients with LVDD, the addition of pioglitazone to oral conventional treatment for 6 months does not induce any adverse or favorable changes in LV diastolic or systolic function despite improvements in glycaemic control, insulin sensitivity, lipid profile, and blood pressure.
Περιγραφή
Λέξεις-κλειδιά
Aged, Blood Pressure/drug effects, Diabetes Mellitus, Type 2/*complications/*drug therapy, Diastole, Echocardiography, Doppler, Heart Function Tests/drug effects, Humans, Hyperglycemia/complications/drug therapy, Hypoglycemic Agents/*administration & dosage, Insulin Resistance, Middle Aged, Systole, Thiazolidinediones/*administration & dosage, Treatment Failure, *Ventricular Dysfunction, Left/complications/drug therapy/ultrasonography
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/20863381
http://www.cardiab.com/content/pdf/1475-2840-9-57.pdf
http://www.cardiab.com/content/pdf/1475-2840-9-57.pdf
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής